LymphedemaV1, Main, Exploration, bibRecord, 008016

Concomitant parasitism: bancroftian filariasis and intestinal helminths and response to albendazole.

Identifieur interne : 008016 ( Main/Exploration ); précédent : 008015; suivant : 008017

Concomitant parasitism: bancroftian filariasis and intestinal helminths and response to albendazole.

Auteurs : Prakash K. Sahoo [Inde] ; Ashok K. Satapathy ; Edwin Michael ; Balachandran Ravindran

Source :

The American journal of tropical medicine and hygiene [ 0002-9637 ] ; 2005.

RBID : pubmed:16282297

Descripteurs français

KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Albendazole (administration et posologie), Albendazole (usage thérapeutique), Animaux, Ascaridiose (), Ascaridiose (parasitologie), Ascaridiose (traitement médicamenteux), Ascaris (), Femelle, Filaricides (administration et posologie), Filaricides (usage thérapeutique), Filariose lymphatique (), Filariose lymphatique (parasitologie), Filariose lymphatique (traitement médicamenteux), Humains, Mâle, Parasitoses intestinales (), Parasitoses intestinales (parasitologie), Parasitoses intestinales (traitement médicamenteux), Parasitémie (parasitologie), Parasitémie (traitement médicamenteux), Résultat thérapeutique, Strongyloides (), Strongyloïdose (), Strongyloïdose (parasitologie), Strongyloïdose (traitement médicamenteux), Wuchereria bancrofti ().
MESH :
- administration et posologie : Albendazole, Filaricides.
- parasitologie : Ascaridiose, Filariose lymphatique, Parasitoses intestinales, Parasitémie, Strongyloïdose.
- traitement médicamenteux : Ascaridiose, Filariose lymphatique, Parasitoses intestinales, Parasitémie, Strongyloïdose.
- usage thérapeutique : Albendazole, Filaricides.
- Adolescent, Adulte, Adulte d'âge moyen, Animaux, Ascaridiose, Ascaris, Femelle, Filariose lymphatique, Humains, Mâle, Parasitoses intestinales, Résultat thérapeutique, Strongyloides, Strongyloïdose, Wuchereria bancrofti.

English descriptors

KwdEn :
- Adolescent, Adult, Albendazole (administration & dosage), Albendazole (therapeutic use), Animals, Ascariasis (complications), Ascariasis (drug therapy), Ascariasis (parasitology), Ascaris (drug effects), Elephantiasis, Filarial (complications), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (parasitology), Female, Filaricides (administration & dosage), Filaricides (therapeutic use), Humans, Intestinal Diseases, Parasitic (complications), Intestinal Diseases, Parasitic (drug therapy), Intestinal Diseases, Parasitic (parasitology), Male, Middle Aged, Parasitemia (drug therapy), Parasitemia (parasitology), Strongyloides (drug effects), Strongyloidiasis (complications), Strongyloidiasis (drug therapy), Strongyloidiasis (parasitology), Treatment Outcome, Wuchereria bancrofti (drug effects).
MESH :
- chemical , administration & dosage : Albendazole, Filaricides.
- chemical , therapeutic use : Albendazole, Filaricides.
- complications : Ascariasis, Elephantiasis, Filarial, Intestinal Diseases, Parasitic, Strongyloidiasis.
- drug effects : Ascaris, Strongyloides, Wuchereria bancrofti.
- drug therapy : Ascariasis, Elephantiasis, Filarial, Intestinal Diseases, Parasitic, Parasitemia, Strongyloidiasis.
- parasitology : Ascariasis, Elephantiasis, Filarial, Intestinal Diseases, Parasitic, Parasitemia, Strongyloidiasis.
- Adolescent, Adult, Animals, Female, Humans, Male, Middle Aged, Treatment Outcome.

Abstract

Subjects in an disease-endemic area in Orissa, India concomitantly infected with filariasis and intestinal helminths had significantly lower intensity of filarial infection in comparison with those who were infected only with filariasis. Administration of albendazole resulted in a significant decrease in the prevalence of filarial antigenemia in subjects concomitantly infected with intestinal helminths, but produced little change in this infection measure in subjects infected only with Wuchereria bancrofti. These results indicate that intestinal helminths could play a role in the anti-filarial activity of albendazole, most probably by depressing filarial infection intensity in co-infected individuals. Confirmation of these findings in a larger cohort may yield important new insights regarding the role of using albendazole in the ongoing intervention programs for the control of lymphatic filariasis.

PubMed: 16282297

Affiliations:

Inde

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Concomitant parasitism: bancroftian filariasis and intestinal helminths and response to albendazole.</title>
<author><name sortKey="Sahoo, Prakash K" sort="Sahoo, Prakash K" uniqKey="Sahoo P" first="Prakash K" last="Sahoo">Prakash K. Sahoo</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Immunology, Regional Medical Research Centre, Indian Council of Medical Research, Bhubaneswar, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Division of Immunology, Regional Medical Research Centre, Indian Council of Medical Research, Bhubaneswar</wicri:regionArea>
<wicri:noRegion>Bhubaneswar</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Satapathy, Ashok K" sort="Satapathy, Ashok K" uniqKey="Satapathy A" first="Ashok K" last="Satapathy">Ashok K. Satapathy</name>
</author>
<author><name sortKey="Michael, Edwin" sort="Michael, Edwin" uniqKey="Michael E" first="Edwin" last="Michael">Edwin Michael</name>
</author>
<author><name sortKey="Ravindran, Balachandran" sort="Ravindran, Balachandran" uniqKey="Ravindran B" first="Balachandran" last="Ravindran">Balachandran Ravindran</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:16282297</idno>
<idno type="pmid">16282297</idno>
<idno type="wicri:Area/PubMed/Corpus">003B58</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003B58</idno>
<idno type="wicri:Area/PubMed/Curation">003B58</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003B58</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003B58</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003B58</idno>
<idno type="wicri:Area/Ncbi/Merge">002021</idno>
<idno type="wicri:Area/Ncbi/Curation">002021</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002021</idno>
<idno type="wicri:doubleKey">0002-9637:2005:Sahoo P:concomitant:parasitism:bancroftian</idno>
<idno type="wicri:Area/Main/Merge">008235</idno>
<idno type="wicri:Area/Main/Curation">008016</idno>
<idno type="wicri:Area/Main/Exploration">008016</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Concomitant parasitism: bancroftian filariasis and intestinal helminths and response to albendazole.</title>
<author><name sortKey="Sahoo, Prakash K" sort="Sahoo, Prakash K" uniqKey="Sahoo P" first="Prakash K" last="Sahoo">Prakash K. Sahoo</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Immunology, Regional Medical Research Centre, Indian Council of Medical Research, Bhubaneswar, India.</nlm:affiliation>
<country xml:lang="fr">Inde</country>
<wicri:regionArea>Division of Immunology, Regional Medical Research Centre, Indian Council of Medical Research, Bhubaneswar</wicri:regionArea>
<wicri:noRegion>Bhubaneswar</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Satapathy, Ashok K" sort="Satapathy, Ashok K" uniqKey="Satapathy A" first="Ashok K" last="Satapathy">Ashok K. Satapathy</name>
</author>
<author><name sortKey="Michael, Edwin" sort="Michael, Edwin" uniqKey="Michael E" first="Edwin" last="Michael">Edwin Michael</name>
</author>
<author><name sortKey="Ravindran, Balachandran" sort="Ravindran, Balachandran" uniqKey="Ravindran B" first="Balachandran" last="Ravindran">Balachandran Ravindran</name>
</author>
</analytic>
<series><title level="j">The American journal of tropical medicine and hygiene</title>
<idno type="ISSN">0002-9637</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Albendazole (administration & dosage)</term>
<term>Albendazole (therapeutic use)</term>
<term>Animals</term>
<term>Ascariasis (complications)</term>
<term>Ascariasis (drug therapy)</term>
<term>Ascariasis (parasitology)</term>
<term>Ascaris (drug effects)</term>
<term>Elephantiasis, Filarial (complications)</term>
<term>Elephantiasis, Filarial (drug therapy)</term>
<term>Elephantiasis, Filarial (parasitology)</term>
<term>Female</term>
<term>Filaricides (administration & dosage)</term>
<term>Filaricides (therapeutic use)</term>
<term>Humans</term>
<term>Intestinal Diseases, Parasitic (complications)</term>
<term>Intestinal Diseases, Parasitic (drug therapy)</term>
<term>Intestinal Diseases, Parasitic (parasitology)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parasitemia (drug therapy)</term>
<term>Parasitemia (parasitology)</term>
<term>Strongyloides (drug effects)</term>
<term>Strongyloidiasis (complications)</term>
<term>Strongyloidiasis (drug therapy)</term>
<term>Strongyloidiasis (parasitology)</term>
<term>Treatment Outcome</term>
<term>Wuchereria bancrofti (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Albendazole (administration et posologie)</term>
<term>Albendazole (usage thérapeutique)</term>
<term>Animaux</term>
<term>Ascaridiose ()</term>
<term>Ascaridiose (parasitologie)</term>
<term>Ascaridiose (traitement médicamenteux)</term>
<term>Ascaris ()</term>
<term>Femelle</term>
<term>Filaricides (administration et posologie)</term>
<term>Filaricides (usage thérapeutique)</term>
<term>Filariose lymphatique ()</term>
<term>Filariose lymphatique (parasitologie)</term>
<term>Filariose lymphatique (traitement médicamenteux)</term>
<term>Humains</term>
<term>Mâle</term>
<term>Parasitoses intestinales ()</term>
<term>Parasitoses intestinales (parasitologie)</term>
<term>Parasitoses intestinales (traitement médicamenteux)</term>
<term>Parasitémie (parasitologie)</term>
<term>Parasitémie (traitement médicamenteux)</term>
<term>Résultat thérapeutique</term>
<term>Strongyloides ()</term>
<term>Strongyloïdose ()</term>
<term>Strongyloïdose (parasitologie)</term>
<term>Strongyloïdose (traitement médicamenteux)</term>
<term>Wuchereria bancrofti ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Albendazole</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Albendazole</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Ascariasis</term>
<term>Elephantiasis, Filarial</term>
<term>Intestinal Diseases, Parasitic</term>
<term>Strongyloidiasis</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Ascaris</term>
<term>Strongyloides</term>
<term>Wuchereria bancrofti</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Ascariasis</term>
<term>Elephantiasis, Filarial</term>
<term>Intestinal Diseases, Parasitic</term>
<term>Parasitemia</term>
<term>Strongyloidiasis</term>
</keywords>
<keywords scheme="MESH" qualifier="parasitologie" xml:lang="fr"><term>Ascaridiose</term>
<term>Filariose lymphatique</term>
<term>Parasitoses intestinales</term>
<term>Parasitémie</term>
<term>Strongyloïdose</term>
</keywords>
<keywords scheme="MESH" qualifier="parasitology" xml:lang="en"><term>Ascariasis</term>
<term>Elephantiasis, Filarial</term>
<term>Intestinal Diseases, Parasitic</term>
<term>Parasitemia</term>
<term>Strongyloidiasis</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Ascaridiose</term>
<term>Filariose lymphatique</term>
<term>Parasitoses intestinales</term>
<term>Parasitémie</term>
<term>Strongyloïdose</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Animals</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Animaux</term>
<term>Ascaridiose</term>
<term>Ascaris</term>
<term>Femelle</term>
<term>Filariose lymphatique</term>
<term>Humains</term>
<term>Mâle</term>
<term>Parasitoses intestinales</term>
<term>Résultat thérapeutique</term>
<term>Strongyloides</term>
<term>Strongyloïdose</term>
<term>Wuchereria bancrofti</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Subjects in an disease-endemic area in Orissa, India concomitantly infected with filariasis and intestinal helminths had significantly lower intensity of filarial infection in comparison with those who were infected only with filariasis. Administration of albendazole resulted in a significant decrease in the prevalence of filarial antigenemia in subjects concomitantly infected with intestinal helminths, but produced little change in this infection measure in subjects infected only with Wuchereria bancrofti. These results indicate that intestinal helminths could play a role in the anti-filarial activity of albendazole, most probably by depressing filarial infection intensity in co-infected individuals. Confirmation of these findings in a larger cohort may yield important new insights regarding the role of using albendazole in the ongoing intervention programs for the control of lymphatic filariasis.</div>
</front>
</TEI>
<affiliations><list><country><li>Inde</li>
</country>
</list>
<tree><noCountry><name sortKey="Michael, Edwin" sort="Michael, Edwin" uniqKey="Michael E" first="Edwin" last="Michael">Edwin Michael</name>
<name sortKey="Ravindran, Balachandran" sort="Ravindran, Balachandran" uniqKey="Ravindran B" first="Balachandran" last="Ravindran">Balachandran Ravindran</name>
<name sortKey="Satapathy, Ashok K" sort="Satapathy, Ashok K" uniqKey="Satapathy A" first="Ashok K" last="Satapathy">Ashok K. Satapathy</name>
</noCountry>
<country name="Inde"><noRegion><name sortKey="Sahoo, Prakash K" sort="Sahoo, Prakash K" uniqKey="Sahoo P" first="Prakash K" last="Sahoo">Prakash K. Sahoo</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008016 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008016 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:16282297
   |texte=   Concomitant parasitism: bancroftian filariasis and intestinal helminths and response to albendazole.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:16282297" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

Serveur d'exploration sur le lymphœdème

Concomitant parasitism: bancroftian filariasis and intestinal helminths and response to albendazole.

Concomitant parasitism: bancroftian filariasis and intestinal helminths and response to albendazole.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.